Article
Heparin-binding motif mutations of human diamine oxidase allow the development of a…
eLife · 2021 · Elisabeth Gludovacz, author Kornelia Schuetzenberger, author Marlene Resch, author Katharina Tillmann, author Karin Petroczi, author Markus Schosserer, author Sigrid Vondra, author Serhii Vakal, author Gerald Klanert, author Jürgen Pollheimer, author Tiina A Salminen, author Bernd Jilma, author Nicole Borth, author Thomas Boehm, author ([email protected]) Arduino A Mangoni, editor Betty Diamond, senior_editor
Key facts
| Title | Heparin-binding motif mutations of human diamine oxidase allow the development of a first-in-class histamine-degrading biopharmaceutical |
|---|---|
| First author | Elisabeth Gludovacz, author Kornelia Schuetzenberger, author Marlene Resch, author Katharina Tillmann, author Karin Petroczi, author Markus Schosserer, author Sigrid Vondra, author Serhii Vakal, author Gerald Klanert, author Jürgen Pollheimer, author Tiina A Salminen, author Bernd Jilma, author Nicole Borth, author Thomas Boehm, author ([email protected]) Arduino A Mangoni, editor Betty Diamond, senior_editor |
| Journal | eLife |
| Published | Sep 3, 2021 |
| DOI | 10.7554/eLife.68542 |
| Devices mentioned | K040782, K042152, K073490, K810810, K940422, K982100 |
| Product codes mentioned | CFN, DFZ, DHX, JAK, GGK, JJH, JQP, MVU |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1